Reports
Global CAR T-Cell Therapy Market Share, Size, Trends, Growth, Forecast: By Drug Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleuce, Idecabtagene Vicleucel, Ciltacabtegene Autoleucel, Others; By Targeted Antigen; By Application; Regional Analysis; Supplier Landscape; 2023-2031
Global CAR T-Cell Therapy Market Outlook
The CAR T-cell therapy market size attained a value of USD 1.9 billion in 2022, driven by the rising prevalence of cancer. The market is anticipated to grow at a CAGR of 14.50% during the forecast period of 2023-2031 to attain a value of nearly USD 6.42 billion by 2031, driven by the rising technological advancements in the healthcare sector.
CAR T-Cell Therapy Market: Introduction and Insight
CAR (Chimeric antigen receptor) T-cell therapy is one of the most recent treatment methods for cancer. It involves the alteration of immune cell which can help in attacking the cancer cell and prevent further production of tumour cells. In this therapy, white blood cell or immune cell, known as T-Cell, are boosted in labs to destroy cancer cell. T-cell is extracted from the patient’s blood and then these cells are altered at the lab with the addition of a receptor called Chimeric antigen receptor or CAR. These altered cells are then added back to the patient’s body.
It is quite similar to cell-based gene therapy since CAR T-cell therapy also involves the alteration of immune cell to attack and destroy the cancer cells. The latter is used for cancers which do not react well to other treatments. The immune system detects foreign substances that enter the body by looking for antigens (proteins) on the surface of these cells. Each cancer has different antigens and would react differently to treatments; thus, these CARs are made according to the type of antigen present in the cancer patient.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
CAR T-Cell Therapy Market Segmentations
The market can be segmented into drug type, targeted antigen, application, and major regions.
Market Breakup by Market by Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel43
- Brexucabtagene Autoleucel
- Lisocabtagene Maraleuce
- Idecabtagene Vicleucel
- Ciltacabtegene Autoleucel
- Others
Market Breakup by Targeted Antigen
- CD19
- BCMA
- HER2
- GD2
- CD22
- CD30
- CD33
- Meso
- Egfrvll
- Others
Market Breakup by Application
- Acute Lymphocytic Leukaemia
- Chronic Lymphocytic Leukaemia
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
CAR T-Cell Therapy Market Scenario
The growth of the CAR T-cell therapy market is driven by rising prevalence of cancer, rising support from the government to increase the awareness about different types of cancers and their treatments, and rising investment in the research and development of new technologies and treatments.
The market has been witnessing growth due to the rising prevalence of cancer due to the unhealthy lifestyles. Along with that, the product pipeline has been quite interesting with the rising investments by the key players.
Based on regions, North America has been leading the global market due to the increased awareness about cancer in the region, along with the higher presence of the leading key players in the region. Apart from North America, the Asia Pacific region is also likely to witness fast growth in the coming years. This rapid growth can be attributed to the developing healthcare sector in the region, rising investments, and rising initiatives and programs by the governments to increase awareness among people. China, India, Asia Pacific, and Korea are among the leading countries in the region and are likely to witness significant developments in the forecast period.
Moreover, there has been a rapid increase in the number of deals and collaborations among the key players to develop and innovate new technologies and drugs. These factors are anticipated to propel the growth of the market in the coming years.
Based on drug type, the market has been dominated by Axicabtagene Ciloleucel in 2022 and is likely to be dominated the same drug in the coming years as well. The active ingredient is available in a medication called Yescarta and it plays a significant role in the treatment of cancer. Other drug types are also witnessing robust demand due to the rising prevalence of cancer across the world.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the CAR T-cell therapy market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Autolus Therapeutics
- CARsgen Therapeutics Co.Ltd.
- Juno Therapeutics, Inc.
- Sorrento Therapeutics, Inc.
- Bluebird bio, Inc.
- CELGENE CORPORATION
- Eureka Therapeutics Inc.
- Avacta Life Sciences Ltd.
- Calyxt Inc.
- Celyad Oncology SA
- Fortress Biotech, Inc
- IMMUNE THERAPEUTICS, INC
- Gilead Sciences, Inc.
- Novartis AG
- Alaunos Therapeutics, Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Targeted Antigen |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global CAR T-Cell Therapy Market Overview
3.1 Global CAR T-Cell Therapy Market Historical Value (2016-2022)
3.2 Global CAR T-Cell Therapy Market Forecast Value (2023-2031)
4 Global CAR T-Cell Therapy Market Landscape
4.1 Global CAR T-Cell Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global CAR T-Cell Therapy Product Landscape
4.2.1 Analysis by Drug Type
4.2.2 Analysis by Target Antigen
4.2.3 Analysis by Applications
5 Global CAR T-Cell Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global CAR T-Cell Therapy Market Segmentation
6.1 Global CAR T-Cell Therapy Market by Drug Type
6.1.1 Market Overview
6.1.2 Axicabtagene Ciloleucel
6.1.3 Tisagenlecleucel
6.1.4 Brexucabtagene Autoleucel
6.1.5 Lisocabtagene Maraleuce
6.1.6 Idecabtagene Vicleucel
6.1.7 Ciltacabtegene Autoleucel
6.1.8 Others
6.2 Global CAR T-Cell Therapy Market by Targeted Antigen
6.2.1 CD19
6.2.2 BCMA
6.2.3 HER2
6.2.4 GD2
6.2.5 CD22
6.2.6 CD30
6.2.7 CD33
6.2.8 Meso
6.2.9 Egfrvll
6.2.10 Others
6.3 Global CAR T-Cell Therapy Market by Application
6.3.1 Market Overview
6.3.2 Acute Lymphocytic Leukemia
6.3.3 Chronic Lymphocytic Leukemia
6.3.4 Diffuse Large B-Cell Lymphoma (DLBCL)
6.3.5 Follicular Lymphoma
6.3.6 Mantle Cell Lymphoma
6.3.7 Multiple Myeloma
6.3.8 Glioblastoma
6.3.9 Sarcoma
6.3.10 Neuroblastoma
6.3.11 Acute Myeloid Leukemia
6.3.12 Breast Cancer
6.3.13 Pancreatic Cancer
6.3.14 Hepatocellular Carcinoma
6.3.15 Colorectal Cancer
6.3.16 Others
6.4 Global CAR T-Cell Therapy Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America CAR T-Cell Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe CAR T-Cell Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific CAR T-Cell Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America CAR T-Cell Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa CAR T-Cell Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Autolus Therapeutics
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 CARsgen Therapeutics Co.Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Juno Therapeutics, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sorrento Therapeutics, Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Bluebird bio, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 CELGENE CORPORATION
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Eureka Therapeutics Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Avacta Life Sciences Ltd.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Calyxt Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Celyad Oncology SA
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Fortress Biotech, Inc
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 IMMUNE THERAPEUTICS, INC
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Gilead Sciences, Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Novartis AG
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Alaunos Therapeutics, Inc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global CAR T-Cell Therapy Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 1.9 billion in 2022.
The market is anticipated to grow at a 14.50% during the forecast period of 2023-2031 to attain a value of nearly USD 6.42 billion by 2031.
The growing prevalence of cancer, rapid increase in research and development, growing number of strategic key players, and novel product launches and approvals are driving the market growth.
The key trends in the market include the rising technological advancements in the healthcare sector, along with the rising support from the government.
The regions involved in the CAR T-cell therapy market are North America, the Middle East and Africa, Latin America, Asia Pacific, and Europe.
The drug types can be categorised into Axicabtagene Ciloleucel, Tisagenlecleucel43, Brexucabtagene Autoleucel, Lisocabtagene Maraleuce, Idecabtagene Vicleucel, and Ciltacabtegene Autoleucel, among others.
The targeted antigens include CD19, BCMA, HER2, GD2, CD22, CD30, CD33, Meso, and Egfrvll, among others.
The therapy finds applications in acute lymphocytic leukaemia, chronic lymphocytic leukaemia, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, glioblastoma, sarcoma, neuroblastoma, acute myeloid leukaemia, breast cancer, pancreatic cancer, hepatocellular carcinoma, and colorectal cancer, among others.
The key companies involved in this market are Autolus Therapeutics, CARsgen Therapeutics Co.Ltd., Juno Therapeutics, Inc., Sorrento Therapeutics, Inc., Bluebird bio, Inc., CELGENE CORPORATION, Eureka Therapeutics Inc., Avacta Life Sciences Ltd., Calyxt Inc., Celyad Oncology SA, Fortress Biotech, Inc, IMMUNE THERAPEUTICS, INC, Gilead Sciences, Inc., Novartis AG, and Alaunos Therapeutics, Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER